同型半胱氨酸对血管性认知障碍患者的影响

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (554 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To find out whether reducing homocysteine (Hcy) levels can delay the cognitive decline in patients with vascular encephalopathy and cognitive impairment. Methods Between July 2015 and June 2018, 77 patients with vascular encephalopathy and cognitive impairment were selected. According to the Hcy level of patients, 45 patients were assigned to the normal group and 32 to the elevation group. After 6, 12 and 18 months of treatment, the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA)were carried out in the two groups respectively. The results of both types of examination were analyzed to evaluate the change of patients' cognitive impairment. Results The decrease rate of the MMSE score in the normal group was significantly lower than that in the elevation group (P<0.05). The MOCA scores of the two groups decreased at 6, 12 and 18 months after treatment, but the scores of orientation, delayed recall, visual perception, naming, attention and total scores of the normal group were higher than those of the elevation group, and the decrease rate was slower. The difference was statistically significant (P<0.05). Conclusions Lowering Hcy levels to normal can slow down the development of cognitive impairment in patients with vascular encephalopathy and cognitive impairment, and the treatment with folic acid and B vitamins can also slow down cognitive impairment.

Key words： homocysteine non demented cognitive impairment ischemic cerebrovascular disease

Received: 20 December 2019

ZTFLH:

R743.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Lijun
	HAN Zhiqun
	DENG Xin

Cite this article:

LIU Lijun,HAN Zhiqun,DENG Xin. Effect of homocysteine on patients with vascular cognitive impairment[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2020, 31(6): 483-485.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2020/V31/I6/483

[1]	Hyuk S K ,Dongwhane L M, Hwan L, et al. Post stroke cognitive impairment as an independent predictor of ischemic stroke recurrence: PICASSO substudy[J]. J Neurology,2020,267(3):688-693.
[2]	陈建媚,张旭,茅新蕾. 脑小血管病患者轻度认知功能障碍与血浆同型半胱氨酸、hs-CRP 水平的相关性研究[J]. 中华全科医学,2016,14(2):203 -205.
[3]	Smith A D, Refsum H, Bottiglieri T,et al. Homocysteine and dementia:an international consensus statement[J]. J Alz Dis,2018,62(2):561-570.
[4]	Smith A D, Refsum H.Homocysteine B vitamins and cognitive impairment[J]. Annu Rev Nutr,2016, 36: 211-239.
[5]	周小炫,谢敏,陶静,等.简易智能精神状态检查量表的研究和应用[J].中国康复医学杂志,2016,31(6):694-696.
[6]	唐煜,郝单单,秦玮,等. 年龄对轻度认知障碍患者蒙特利尔认知评估量表基本版得分的影响[J].武警医学, 2019, 30(9):787-790.
[7]	詹媛,张玉萍,李雷利. 高同型半胱氨酸血症与脑血管疾病相关性的研究进展[J]. 中华临床医师杂志(电子版),2017,11(3):506-509.
[8]	卢健聪,谢海群,王玉凯,等. 高同型半胱氨酸血症与脑小血管病的研究进展[J]. 中华神经科杂志,2016,49(6):495-498.
[9]	Dam F, Gool W A.Hyperhomocysteinemia and alzheimer's disease: a systematic review[J]. Arch Gerontol Geriatr,2009,48:425-430.
[10]	Smith A D, Refsum H. Dementia prevention by disease-modification through nutrition[J]. J Prev Alzheimers Dis,2017,4:138-139.
[11]	董珍,朱婷珂 .同型半胱氨酸与痴呆:国际共识声明[J]. Chin J Stroke, 2019, 14(2): 142-148.
[12]	张惠霞,王胜利,张星,血浆同型半胱氨酸水平与老年痴呆的关系[J]. 医学理论与实践,2019,32(15):2446-2448.